Bio-Rad Laboratories ( (BIO) ) has released its Q2 earnings. Here is a breakdown of the information Bio-Rad Laboratories presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bio-Rad Laboratories, Inc., based in Hercules, California, is a prominent player in the life sciences and clinical diagnostics sectors, known for its innovative products that advance scientific research and healthcare diagnostics globally.
In its second-quarter 2025 financial report, Bio-Rad Laboratories announced a modest revenue increase, alongside strategic expansion through the acquisition of Stilla Technologies, enhancing its Droplet Digital PCR offerings. The company also reported a significant net income improvement due to favorable changes in investment valuations.
Key financial metrics for the quarter included a 2.1% increase in revenue to $651.6 million compared to the previous year. The Life Science segment saw a 4.9% rise in sales, driven by process chromatography and food safety products, while the Clinical Diagnostics segment remained flat, impacted by reduced diabetes testing reimbursements in China. The company’s net income surged to $317.8 million from a loss in the previous year, largely due to a change in the fair market value of its investment in Sartorius AG.
Looking ahead, Bio-Rad has updated its full-year 2025 financial outlook, now expecting non-GAAP, currency-neutral revenue growth of 0 to 1.0% and an improved operating margin estimate of 12.0 to 13.0%. This reflects the company’s strategic focus on expanding its product offerings and managing expenses effectively in a dynamic market environment.